---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-26-000002"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2026-01-21T23:59:59+00:00"
generated_at: "2026-05-16T09:22:00.091715+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# JNJ Q4 2025 sales $24.6B (+9.1% YoY), net earnings $5.1B ($2.10 EPS); adj. EPS $2.46

## Summary
- Q4 sales $24,564M (+9.1% YoY); full-year sales $94,193M (+6.0% YoY).
- Q4 net earnings $5,116M ($2.10 diluted EPS) vs $3,431M ($1.41) a year ago.
- Adjusted Q4 net earnings $6,009M ($2.46 adj. diluted EPS) vs $4,946M ($2.04).
- R&D expense decreased 19.7% YoY to $4,252M; effective tax rate was -3.0%.
- MedTech segment sales $8,801M (+7.5% YoY); Innovative Medicine $15,763M (+10.0% YoY).

## SEC filing metadata
- accession: 0000200406-26-000002
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2026-01-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040626000002/0000200406-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040626000002/jnj-20260121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-26-000002
- JSON: https://secwatch.observer/filing/0000200406-26-000002.json
- Plain text: https://secwatch.observer/filing/0000200406-26-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.